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their characteristics and monitor treatment and outcomes. The system allows
longitudinal entry of well-known Patient Reported Outcome instruments (e.g. QO-
LIE-31-P, HADS), treatments, symptoms, and seizure frequency and severity.
RESULTS: By September 2010, 2613 patients had registered; 1838 (70.3%) patients
with a reported diagnosis of epilepsy were analyzed. The PatientsLikeMe® Epilepsy
Community tends to over-represent females compared with PharMetrics® (71.7%
vs. 53.6%) and 20–50 year old patients, reflecting online user demographics. The
proportions of treated patients receiving polytherapy or newer AEDs were also
greater in PatientsLikeMe® versus PharMetrics® (53.4% vs. 29.2%; 82.4% vs. 66.4%,
respectively). Regional coverage of PatientsLikeMe® members appeared closer to
US census than PharMetrics®. Patient-reported data from PatientsLikeMe® re-
flected the significant burden of epilepsy on patients’ lives. Patients experiencing
1 seizure during the last 4 weeks reported significantly lower quality of life (QoL)
and higher levels of depression and anxiety than those not reporting seizures (all
p-values 0.005). This was even more pronounced in patients reporting 1 gener-
alized tonic-clonic seizure (all p-values 0.001). Driving status was clearly im-
pacted by epilepsy; 50.6% in the PatientsLikeMe® sample did not drive (86.2% of
these because of epilepsy) and 37.4% of drivers limited their driving because of
epilepsy. Patients with driving limitations reported lower health-related QoL and
higher levels of anxiety and depression (all p-values 0.0001). CONCLUSIONS: By
sharing their records online,members of the PatientsLikeMe® Epilepsy Community
provide researchers with a unique source of information. Exploring these data
provides insight into the disease burden, treatment patterns and associated out-
comes. UCB-sponsored.
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In a multicenter, double-blind trial, Dysport 500 units was compared to placebo
in the treatment of cervical dystonia. The primary efficacy response was eval-
uated using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
Pain was evaluated with the Pain subscale of the TWSTRS and a self-reported
pain visual analog scale (VAS). HRQL was assessed using the SF-36 Health Sur-
vey (SF-36). OBJECTIVES: To evaluate improvements in health-related quality of
life (HRQL) with in patients with cervical dystonia enrolled in a randomized clinical
trial with Dysport™ (also known as abobotulinumtoxinA for Injection in the United
States). METHODS: Eighty patients were randomly assigned to receive one treat-
ment with Dysport 500 units or placebo. Participants were assessed at baseline and
weeks 2, 4, 8, 12, 16, and 20 after treatment. To evaluate HRQL, changes from
baseline toWeek 8 on the 8 SF-36 domains, the TWSTRS Pain subscale, and the pain
VAS were compared. RESULTS: TWSTRS total scores were significantly improved
with Dysport at weeks 4, 8, and 12 (P  0.013 when compared with placebo). Im-
provements from baseline to week 8 were seen for all 8 SF-36 domains in the
Dysport group. The largest improvements occurred in the Role–Physical and Bodily
Pain domains. The placebo group showed some decrease (worsening) in Physical
Functioning and little to no change in other SF-36 domains. The differences in
mean change scoreswere statistically significant between the Dysport and placebo
for 5 of the 8 domains (Physical Functioning, Role–Physical, Bodily Pain, General
Health, and Role–Emotional [P  0.03 for all]). Improvement in the Bodily Pain
domain was also supported by significant improvements in the TWSTRS Pain sub-
scale and the pain VAS at week 4. CONCLUSIONS: The data suggest that HRQL is
improved with Dysport, particularly pain improvement and in the SF-36 Physical
Functioning and Role–Physical domains.
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OBJECTIVES: To assess the change in general health-related quality of life (HRQoL)
of multiple sclerosis (MS) patients after one year of natalizumab treatment in the
usual care setting. METHODS: MS patients, newly initiating natalizumab, were
recruited to participate in a longitudinal observational study to assess general
HRQoL using the SF-12v2 prior to natalizumab initiation (baseline, BL) and after the
3rd, 6th and 12th infusions. Higher physical component summary scores (PCS) and
mental component summary scores (MCS) on the SF-12v2 indicate better HRQoL.
Statistical regressionmodels were used to evaluate changes in PCS andMCS scores
from BL through the 12th infusion after controlling for BL covariates such as age,
years sinceMS diagnosis, number of natalizumab infusions received, disability and
functional status, number of MS drugs used prior to natalizumab and comorbidity
burden. RESULTS: Data for 324 patients who completed the baseline through 12th
infusion assessments are reported. The mean age was 46.5 (SD10.4) and the ma-
jority of patients were female (77.8%). The mean number of years since MS diag-
nosis was 10.16 (SD8.23). The adjusted PCS score improved significantly from
baseline (BL 34.25, 12th infusion 36.66; p0.001); similar significant improvements
were observed in the adjusted MCS scores (BL 43.13, 12th infusion 46.77; p0.001).
CONCLUSIONS: Patients reported improvements in general HRQoLmeasures after
one year of natalizumab treatment in the usual care setting. These results are
consistent with results from pivotal clinical trials and document the beneficial
impact of natalizumab on HRQoL in MS patients.
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OBJECTIVES: To develop a single conceptual model of the impact of epilepsy on
adult and pediatric patients with partial onset seizures to guide the identification
of endpoints in clinical trials of new anti-epileptic treatments.METHODS: A liter-
ature review to identify qualitative research investigating the impact of partial
onset seizures on adult and paediatric patients’ lives. Structured Embase/Medline
searches identified 167 abstracts which were screened to identify primary qualita-
tive research among adult and/or pediatric epilepsy patients. Publications were
excluded if they: did not include partial onset seizure patients (with or without
generalised seizures); focused on surgical treatment, were not qualitative research;
were conducted outside of North America/Europe; focused on epilepsy as a sec-
ondary condition. 12 adult and 8 pediatric qualitative studies were identified. Rel-
evant data were extracted into structured tables. Results from both samples were
synthesised into a conceptual model by two experienced qualitative researchers.
RESULTS: Twenty-three concepts were identified from the reviewed literature.
Concepts were largely universal between adult and pediatric patients, although
content of concepts varied between adults and pediatric, for example paediatric
relationship concerns were focused on rejection in friendships and trouble de-
veloping relationships. For adults the concerns were problematic relationships
with spouse or partner, fulfilling family roles and problems having children.
CONCLUSIONS: The conceptual model identifies important impacts of epilepsy
from the patient perspective. The model also demonstrates areas of patients’ lives
thatmay potentially be enhanced through improvement of epilepsy symptoms. As
a result, the model allows for concepts of concern to both adult and pediatric
patients to be identified and explored as potential patient-reported endpoints in
clinical trials of new antiepileptic treatments.
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OBJECTIVES: To describe health-related quality of life (HRQoL) and health utility of
persons with hemophilia B, and to determine the association of these measures
with self-reported joint pain and motion limitation. METHODS: The prospective,
longitudinal Hemophilia Utilization Group Study (HUGS-Vb) recruited participants
with hemophilia B from six U.S. Hemophilia Treatment Centers from June 2009 to
September 2010. At initial interview, participants or their parent(s) answered ques-
tions regarding demographic and clinical characteristics, HRQoL, health utility and
self-reported joint pain and motion limitation. HRQoL measures included Short
Form-12 (SF-12) for adults and PedsQL for children. Health utility measures used
were EQ-5D (adults) and visual analog scale (VAS). RESULTS: Seventy-seven par-
ticipants (48% adults) were recruited. Adultmean SF-12mental (MCS-12) and phys-
ical (PCS-12) component scores were 54.3 (6.13) and 47.1 (11.1) respectively.
Participants with mild/moderate hemophilia (mean50.49.0) had significantly
better PCS-12 scores than those with severe hemophilia (mean42.612.4)
(P0.0390). Mean EQ-5D and VAS scores were 0.85 (0.16) and 85.5 (11.1) respec-
tively, with no significant differences between severity groups. PCS-12 and EQ-5D
each negatively correlated with self-reported joint pain (PCS-12:P0.0001, EQ-5D:
P0.0017) andmotion limitation (PCS-12:P0.0001, EQ-5D:P0.0081); better HRQoL
was associated with less severe pain or limitation. Pediatric mean total PedsQL
score was 85.6 (11.2) with physical (PF) and psychosocial functioning summary
scores of 92 (14.9) and 82 (13.1) respectively. Mean VAS score was 88.6 (14.3).
No significant differences were found between severity groups. PF and VAS scores
each negatively correlated with self-reported joint pain (PF:P0.0127, VAS:
P0.0245) and motion limitation (PF:P0.0009, VAS:P0.0015). CONCLUSIONS:
While previous HRQoL studies have examined hemophilia A and its associated
clinical aspects, this is the first focusing on the hemophilia B population. As hemo-
philia A and B may have different clinical manifestations, HRQoL data on hemo-
philia B can help define disease burden in this group. One limitation is the current
small sample size, which will increase as additional participants continue to be
enrolled.
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OBJECTIVES:Quality of life (QoL) remains an important consideration in the care of
patients presenting with chronic neuromuscular disorder (NMD). The factor struc-
ture of the SF-36 was evaluated in patients with NMD in order to determine the
appropriateness of this instrument to assess QoL in this clinical population.
METHODS: Confirmatory factor analyses were conducted on self-report SF-36 data
from 245 individual’s diagnosedwith NMD. Six structural models of the SF-36 were
evaluated against data. RESULTS: The underlying factor structure of the SF-36 in
NMD was observed to be consistent with contemporary theoretical models of the
instrument. The traditional measurement model of SF-36, however, performed
comparatively poorly. CONCLUSIONS: The use of the SF-36 in individuals with
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NMD can be recommended when eight sub-scales are used and reported. The
suggestion that the SF-36 can be utilized as a two-sub-scale measure of physical
health and mental health components in this clinical group, however, was not
supported because of model fit limitations.
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OBJECTIVES: Quality of life (QoL) is an important psychological dimension in pa-
tients with Parkinson’s disease (PD). The factor structure of the SF-36 in patients
with PD was investigated to determine how this measure might best be used to
assess QoL in this clinical population. METHODS: Confirmatory factor analyses
were conducted on self-report SF-36 data from 339 individuals diagnosed with PD.
Six structural models of the SF-36 were evaluated against data. RESULTS: The
underlying factor structure of the SF-36 in PDwas found to be inconsistentwith the
assumedmeasurement model of SF-36 but consistent with contemporary theoret-
ical models of the instrument. CONCLUSIONS: The use of the SF-36 in individuals
with PD can be recommendedwhen eight subscales are used and reported. The use
of the instrument as a two-subscale measure of physical health andmental health
components, however, was not found.
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OBJECTIVES:The purpose of this studywas to investigate changes in health related
quality of life (HRQOL) experienced by patients with multiple sclerosis (MS) and to
determine their experiences, opinions, and expectations related to disease modi-
fying drugs (DMDs) used in MS. METHODS: A sample of 18 individuals with con-
firmed diagnosis of MS was recruited through a university hospital-based neurol-
ogy clinic. Four focus group (FG) sessions involving semi-structured interviews
were conducted. The FG discussions were audio-recorded and were later tran-
scribed for coding purpose. Qualitative content analysis of transcribed data was
performed by two blinded reviewers using QSR NVivo 8 software. The data were
coded into specific themes as per the research questions. RESULTS: Qualitative
analysis indicated twelve major themes related to HRQOL associated with the dis-
ease condition and experiences with the DMDs used to treat MS: (1) HRQOL before
the diagnosis of MS; (2) HRQOL after the diagnosis of MS; (3) Coping with MS; (4)
Opinions regarding the current DMDs; (5) Clinical benefits; (6) Adverse events as-
sociated with the DMDs; (7) Side effects associated with DMDs; (8) Treatment ad-
herence; (9) Convenience of DMD administration; (10) Treatment satisfaction; (11)
Expectations from the future DMDs; and (12) Cost associatedwith DMDs. HRQOL in
social, physical, and psychological domains declined considerably among all par-
ticipants since the diagnosis of MS. Participants were content with clinical benefits
associated with DMDs they were currently taking. Future DMDs were expected to
be safer and easier to administer. CONCLUSIONS: This study provides an in-depth
understanding of the various factors that affect HRQOL of patients living with MS
and the characteristics of DMDs that are ofmost value toMS patients. Study results
support the need to determine patient preferences for specific adverse events as-
sociated with DMDs against the clinical benefits in order to improve adherence
with DMDs and consequent outcomes.
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OBJECTIVES: To assess the impact of the Medicare Part D coverage gap and co-pay
levels on medication utilization behaviors among beneficiaries taking disease
modifying drugs (DMDs) for the treatment of multiple sclerosis (MS).METHODS: A
retrospective cohort study was conducted using a 5% national sample of Medicare
beneficiaries for 2007. Ambulatory patients diagnosed with MS and taking at least
one DMD were included. Adherence was measured using proportion of days cov-
ered (PDC). Patients were classified as discontinuing therapy if last day of posses-
sion was more than 60 days before the end of the year. Low income subsidy (LIS)
status was used as a measure of out-of-pocket burden. RESULTS: 1,439 beneficia-
ries with MS and DMD use were identified. 89% reached the coverage gap and 81%
reached catastrophic coverage. Average time in gap was 2 to 4 months for the
different copay groups. Overall PDC measures were 85.7% pre-gap, 81.7% during
gap, and 87.3% in catastrophic coverage. PDC for full year was higher (p0.001) for
no-copay LIS (90.2%) than for reduced-copay LIS (83.7%) and full-copay (79.8%)
beneficiaries. Full-copay beneficiaries were slightly more likely to stop therapy
after hitting the gap than were reduced-copay or no-copay beneficiaries (17.7%,
15.0%, 10.6%). Full-copay beneficiaries were more likely (p0.001) than reduced-
copay or no-copay beneficiaries to have a drop in PDC during the coverage gap
(46.3%, 28.2%, 18.1%). CONCLUSIONS:Most beneficiaries with MS reach the cover-
age gap early in the year and fairly quickly move to catastrophic coverage. Average
time in the coverage gap is limited, but significantly reduces adherence. Higher
out-of-pocket burden is also associated with a reduction in adherence.
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OBJECTIVES: Once-daily armodafinil significantly improves wakefulness in pa-
tients with excessive sleepiness due to shift work disorder (SWD), treated obstruc-
tive sleep apnea (OSA), or narcolepsy. The objective of the current analysis was to
examine resource utilization by patients who received armodafinil for these FDA-
approved indications.METHODS: Data were collected from the IMS LifeLink Data-
base (December 2008 to March 2010) and contained longitudinal patient data from
medical claims (diagnostic/therapeutic services), pharmacy claims (prescriptions),
and eligibility files (demographics and enrollment). Patients were identified and
healthcare utilization data were collected for 6months before and up to 10months
after their first armodafinil pharmacy claim. Healthcare costs and visits before and
after initiation of armodafinil were statistically analyzed using paired t-tests.
RESULTS: 1,282 patients were included (4.5% SWD; 85.9% OSA; 20.4% narcolepsy).
The mean monthly healthcare cost for patients prior to taking armodafinil was
$1,562.99 (pharmacy $432.26; medical $1,130.73). After armodafinil initiation, over-
all monthly cost decreased to $1,438.11 (p0.0588). Armodafinil significantly in-
creased prescription costs by $138.53/month (p0.0001) but decreased medical
costs by $263.41/month (p0.0001). Medical costs were decreased by $133.23 for
physician costs (p0.0001) and $75.62 for outpatient costs (p0.0039). Emergency
room costs were lower by $3.99/month (NS), and inpatient costs were lower by
$7.51/month (NS). The number of inpatient visits were reduced by 0.21/year
(p0.0307), physician visits by 4.91/year (p0.0001), and outpatient visits by 0.89/
year (p0.0001). CONCLUSIONS: After armodafinil treatment, reductions were
seen in healthcare utilization and costs compared to the pre-armodafinil period. As
expected, total prescription costs were greater following initiation of armodafinil
therapy; however, lower total monthly costs were observed with armodafinil be-
cause use of medical resources decreased. This significant reduction in medical
resource utilization appeared to be driven predominantly by fewer physician visits
and lower outpatient costs. This research was sponsored by and conducted in
collaboration with Cephalon, Inc., Frazer, PA.
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OBJECTIVES: Uncontrolled epilepsy is associated with devastating injuries, neuro-
psychiatric impairment, and increased mortality based on clinical observations.
The purpose of this study is to evaluate the clinical and economic burden of un-
controlled epilepsy in a Medicaid population. METHODS: Medical and pharmacy
claims from Florida (1997Q3-2008Q2), Iowa (1998Q1-2006Q2), Kansas (2001Q1-
2009Q2), Missouri (1997Q1-2008Q2), and New Jersey (1997Q1-2008Q4) Medicaid da-
tabaseswere analyzed. Patients18 yearswith epilepsy and receiving antiepileptic
drugs (AEDs) were selected. A retrospective matched-cohort design was used to
classify patients intomutually-exclusive cohorts of “uncontrolled” (2 consecutive
AED changes followed by 1 epilepsy-related inpatient/ER visit), “well-controlled”
(no AED change and no epilepsy-related inpatient/ER visit) and “intermediate”
(neither “uncontrolled” nor “well-controlled”) epilepsy. Patients with uncontrolled
epilepsy were matched 1:1 with those with well-controlled and intermediate epi-
lepsy, respectively, using propensity score matching. Matched cohorts were com-
pared for health care resource utilization, occurrence of negative clinical events,
and direct health care costs. Statistical differences between cohorts were assessed
using multivariate conditional regression models, adjusted for demographics,
treatment characteristics, and comorbidities. RESULTS:Uncontrolled epilepsywas
associated with significantly higher health care resource utilization (adjusted rate
ratios [ARRs] [95% confidence intervals (95%CIs)]: hospitalizations6.65 [6.41-6.90],
length of hospital stays7.72 [7.60-7.84], emergency-room visits3.67 [3.61-3.74],
outpatient visits3.85 [3.77-3.93]) versus well-controlled epilepsy. Morbidity oc-
curred more frequently in the uncontrolled group (ARRs: fractures: 2.16 [2.07-2.26],
motor vehicle accident-related injuries: 2.45 [1.77-3.40], head injuries: 2.09 [2.04-
2.14], status epilepticus events: 9.71 [8.20-11.50]) relative to well-controlled pa-
tients. Patients with uncontrolled epilepsy also incurred higher health care costs
(adjusted cost difference [95%CI]$12,258 [$10,482-$14,083] per patient per year), of
which hospitalization costs represented 46.3%. Results were similar when com-
pared to intermediate epilepsy. CONCLUSIONS: Uncontrolled epilepsy was associ-
atedwith significantly greater health care resource utilization, higher rates ofmor-
bidity, and higher medical costs compared to well-controlled and intermediate
epilepsy.
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RETROSPECTIVE DATABASE ANALYSIS OF FREQUENCY AND COSTS OF
RELAPSES AMONG MULTIPLE SCLEROSIS PATIENTS
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OBJECTIVES: Identify the frequency, severity, and cost of relapses among a multi-
ple sclerosis (MS) population. METHODS: Data was assessed from MarketScan®
Research Database. Patients at least 18 years old with MS, defined at least 2 outpa-
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